Following the launch of its phase I clinical trials for lead candidate CALY-002, Merck Serono spin-off, Calypso Biotech, has secured €8 million in a Series A extension round, bringing the total capital raised to €28 million. The funds will accelerate clinical developments.
Calypso Biotech is a Netherlands-based biotechnology company that researches and develops monoclonal antibodies for the treatment of autoimmune diseases.